In lymphoma and other haematological malignancies, aberrant expression of receptors and mutations in Smads have been found, although the reported frequencies of aberrations involving the TGF-β pathway in lymphoma are lower than in many other cancer types [12,13]. This evidence concerns the gene TGFB1 and cancer.